BBNX
Beta Bionics, Inc.
NASDAQ · Healthcare · Medical - Equipment & Services · US
$17.58
−1.51%Oct 27, 2026, 17:40 UTC
A lawsuit alleges that Beta Bionics, Inc. failed to disclose key facts to investors between July 30, 2025 and February 24, 2026.
Source:Oct 26, 2026, 17:10 UTC
Law Offices of Frank R. Cruz announced a class action lawsuit against Beta Bionics, Inc. on behalf of investors who acquired its securities from July 30, 2025, to February 24, 2026, alleging misleading statements.
Source:Oct 16, 2026, 23:59 UTC
HAGENS BERMAN SOBOL SHAPIRO LLP announced that November 3, 2026, was the deadline to seek appointment as lead plaintiff in the proposed investor lawsuit against Beta Bionics, Inc..
Source:Oct 5, 2026, 07:35 UTC
The DJS Law Group announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Source:Sep 29, 2026, 16:11 UTC
Beta Bionics integrated Senseonics' Eversense 365 continuous glucose monitor into its iLet automated insulin delivery ecosystem.
Source:Sep 29, 2026, 12:00 UTC
Beta Bionics, Inc. announced it plans to release its third quarter 2026 financial results after markets close on October 27, 2026.
Source:Sep 25, 2026, 10:37 UTC
Bleichmar Fonti & Auld LLP announced that a securities fraud class action lawsuit has been filed against Beta Bionics, Inc. and certain senior executives following a 37% drop in the company's stock over medical device safety issues.
Sep 22, 2026, 10:35 UTC
A securities fraud class action lawsuit was filed against Beta Bionics, Inc. and certain senior executives on behalf of investors after the company's stock fell over 37% amid allegations it misled investors about the safety, efficacy, and commercial success of its iLet medical device.
Source:Sep 17, 2026, 11:26 UTC
Beta Bionics, Inc. (BBNX) shares surged 15.3% in the prior trading session on above-average trading volume.
Source:Sep 16, 2026, 14:41 UTC
Beta Bionics priced a public offering of 7,652,175 common shares at $17.25 per share, plus 1,043,484 pre-funded warrants at $17.2499 each, to raise about $150 million before expenses, expected to close around September 17.
Sep 15, 2026, 20:13 UTC
Beta Bionics, Inc. announced a proposed underwritten public offering of $125.0 million of its common stock, with a 30-day underwriter option for up to an additional $18.75 million of shares.
Sep 14, 2026, 11:30 UTC
Beta Bionics received U.S. FDA clearance for its Mint patch pump, a reusable and disposable insulin delivery device with CGM integration and smartphone control.
Sep 14, 2026, 11:00 UTC
Senseonics Holdings announced a strategic partnership with Beta Bionics to integrate the Eversense 365 continuous glucose monitoring system with the iLet Bionic Pancreas, with a planned commercial launch in Q4 2026.
Source:Sep 12, 2026, 01:15 UTC
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Beta Bionics, Inc. on behalf of investors who acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026.
Sep 11, 2026, 18:30 UTC
Law Offices of Howard G. Smith filed a securities class action on behalf of investors who purchased Beta Bionics, Inc. securities between July 30, 2025 and February 24, 2026, with a lead plaintiff motion deadline of November 3, 2026.
Source:Sep 11, 2026, 14:13 UTC
Grabar Law Office announced an investigation into claims on behalf of long-term shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).
Source:Jul 29, 2026, 20:02 UTC
Beta Bionics reported its financial results for the second quarter of 2026 and updated its full year 2026 guidance.